Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study
Journal of Clinical Oncology · 20.08.2026 · 44 (24) · 2271-2277
DOI: 10.1200/jco-26-01042 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.08.2026. Verfasst von Barbara Burtness und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Yale Cancer Center, Yale School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local, Immune Checkpoint Inhibitors, Head and Neck Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Single-agent paclitaxel or cetuximab after immune checkpoint inhibitor (ICI) and chemotherapy demonstrated objective response rates (ORRs) of 21%-24% in recurrent/metastatic (R/M) head/neck squamous cell cancer (HNSCC). Epidermal growth factor receptor (EGFR) and MET are overexpressed in R/M HNSCC. Amivantamab, an EGFR-MET bispecific antibody, may be a rational treatment. Cohort 1 of OrigAMI-4 (ClinicalTrials.gov identifier: NCT06385080 ) evaluated subcutaneous amivantamab administered every 3 weeks in participants with non-human papillomavirus R/M HNSCC after PD-(L)1 inhibitor and platinum-based chemotherapy. Prior anti-EGFR therapy and p16-positive oropharyngeal cancer were exclusionary. The primary end point was RECIST v1.1 ORR. Secondary end points included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. In 102 participants, blinded independent central review‑assessed ORR was 42% (95% CI, 32 to 52); the complete response rate was 15%. Median DoR was not reached (NR; 95% CI, 6.9 to NR); 56% of responses lasted ≥6 months. Investigator-assessed ORR was 47% (95% CI, 37 to 57). At a median follow-up of 11.8 months (range, 1.1-21.9), median PFS and OS were 6.8 months (95% CI, 5.2 to 8.3) and 12.5 months (95% CI, 10.2 to 16.8), respectively. Adverse events were consistent with previous experience with no new safety signals. Treatment-related discontinuations were low (8%). Amivantamab demonstrated greater antitumor activity in participants previously exposed to ICI and chemotherapy than has been reported for paclitaxel or cetuximab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Yale Cancer Center, Yale School of Medicine, New Haven, CT.
- Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL.
- Institut Sainte Catherine, Avignon, France.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.
- Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
- Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
ORCID-Profile: Barbara Burtness, Ari J Rosenberg, Sun Min Lim, Muh-Hwa Yang, Shau-Hsuan Li, Shigenori Kadowaki, Paul L Swiecicki, Jessica L Geiger, Ye Guo, Douglas Adkins, Myung-Ju Ahn, Irene Braña, Hideki Tanaka, Siddharth Sheth, Kiichiro Toyoizumi, Emrullah Yilmaz, Mahadi Baig, Priya Kim, Kevin J Harrington
Zitieren
APA
Burtness, B., Rosenberg, A. J., Calderon, B., Lim, S. M., Yang, M. H., Li, S. H., Kadowaki, S., Swiecicki, P. L., Geiger, J. L., Ince, W., Hahn, D., Guo, Y., Adkins, D., Metcalf, R., Ahn, M. J., Sukari, A., Braña, I., Keam, B., Tanaka, H., …, & OrigAMI-4 Cohort 1 Investigators (2026). Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. Journal of Clinical Oncology, 44(24), 2271-2277. https://doi.org/10.1200/jco-26-01042
Vancouver
Burtness B, Rosenberg AJ, Calderon B, Lim SM, Yang MH, Li SH, et al. Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. Journal of Clinical Oncology. 2026;44(24):2271-2277. doi:10.1200/jco-26-01042
BibTeX
@article{Burtness2026,
author = {Burtness, Barbara and Rosenberg, Ari J and Calderon, Benoit and Lim, Sun Min and Yang, Muh-Hwa and Li, Shau-Hsuan and Kadowaki, Shigenori and Swiecicki, Paul L and Geiger, Jessica L and Ince, William and Hahn, Dennis and Guo, Ye and Adkins, Douglas and Metcalf, Robert and Ahn, Myung-Ju and Sukari, Ammar and Braña, Irene and Keam, Bhumsuk and Tanaka, Hideki and Sheth, Siddharth and Oliva, Marc and Lyu, Xuesong and Curtin, Joshua C and Toyoizumi, Kiichiro and Xie, John and Wade, Mark and Diorio, Brooke and Kapoor, Aastha and Yilmaz, Emrullah and Baig, Mahadi and Kim, Priya and Verheijen, Remy B and Shah, Sujay and Harrington, Kevin J and OrigAMI-4 Cohort 1 Investigators, OrigAMI-4 Cohort 1 Investigators},
title = {Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {24},
pages = {2271--2277},
doi = {10.1200/jco-26-01042}
}
EUVIMED